Search clinical trials for: Symlin

Total 28 results

Boston University
National Institute on Aging (NIA)

Recruiting

Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease (DTAD)

Alzheimer Disease | Mild Cognitive Impairment

United States
Joslin Diabetes Center
Bristol-Myers Squibb

Completed

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Hypoglycemia | Evidence of Previous Gastric Surgery

United States
H. Lee Moffitt Cancer Center and Research Institute

Withdrawn

Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

Cutaneous Squamous Cell Carcinoma

United States
University of Maryland, Baltimore
Amylin Pharmaceuticals, LLC.

Withdrawn

Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM

Type 2 Diabetes
Texas Diabetes & Endocrinology, P.A.
Amylin Pharmaceuticals, LLC.

Terminated

Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

Type 1 Diabetes | Type 2 Diabetes

United States
Adocia

Completed

A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Germany
Adocia

Completed

A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Germany
University of Texas Southwestern Medical Center

Withdrawn

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

Type 1 Diabetes

United States
AstraZeneca
Juvenile Diabetes Research Foundation

Completed

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Albert Einstein College of Medicine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

Type 1 Diabetes

United States
Albert Einstein College of Medicine

Completed

Closed Loop System With Pramlintide Versus Exenatide (Closedloop)

Type 1 Diabetes

United States
Baylor College of Medicine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...

Completed

The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes (T2DM)

Type 2 Diabetes

United States
Baylor College of Medicine

Completed

Continuous Subcutaneous Infusion of Pramlintide and Insulin

Type 1 Diabetes

United States
AstraZeneca

Completed

Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
AstraZeneca

Completed

Evaluation of the Bioavailability of Pramlintide

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
University of Colorado, Denver
Amylin Pharmaceuticals, LLC.

Completed

Pramlintide in Adolescents With Type 1 Diabetes

Type 1 Diabetes

United States
AstraZeneca

Completed

A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Obesity

United States
AstraZeneca

Completed

Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

Obesity | Overweight

United States
AstraZeneca

Completed

Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
AstraZeneca

Completed

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

Obesity

United States
AstraZeneca

Completed

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

Obesity | Overweight

United States
AstraZeneca

Completed

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
AstraZeneca

Completed

A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Obesity

United States
AstraZeneca

Completed

A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
AstraZeneca

Completed

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
AstraZeneca

Completed

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

Obesity | Overweight

United States
AstraZeneca

Completed

A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Cheryl Rosenfeld, DO
Amylin Pharmaceuticals, LLC.

Unknown

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States

3

Subscribe